Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC's Pending Claim Substantiation Changes Will Weigh On Small Firms

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission soon will demand greater substantiation for dietary supplement health claims as the agency aligns its standards for clinical evidence more closely with FDA's

You may also be interested in...



‘Wrong Type Of Expert’ Advised FTC On Phillip’s Colon Health Claims – CRN

FTC’s request that Bayer support claims for Phillip’s Colon Health probiotic supplement with RCTs would set a precedent that would invalidate most structure/function claims, CRN argues, saying FTC’s interpretation of competent and reliable evidence for structure/function claims disregards a wealth of scientific data.

‘Wrong Type Of Expert’ Advised FTC On Phillip’s Colon Health Claims – CRN

FTC’s request that Bayer support claims for Phillip’s Colon Health probiotic supplement with RCTs would set a precedent that would invalidate most structure/function claims, CRN argues, saying FTC’s interpretation of competent and reliable evidence for structure/function claims disregards a wealth of scientific data.

Trade Groups, Emord Rip FTC Interpretation Of POM Wonderful Ads

An amici curiae brief filed in the POM Wonderful case by CHPA and CRN criticizes FTC for relying “on its own ‘expertise’ to determine the meaning of ambiguous advertisements.” A separate brief by attorney Jonathan Emord says FTC is creating unreasonable barriers for food product research.

Related Content

Topics

UsernamePublicRestriction

Register

PS103843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel